Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D.
Frida WelanderHenrik RenlundEmöke DiményHenrik HolmbergAnders SjälanderPublished in: Clinical kidney journal (2022)
Warfarin treatment is associated with a lower risk of ischaemic stroke for patients with NVAF and G3, G4 and G5D at the cost of a higher risk of major bleeding for G4-G5D. Existing observational data are conflicting, stressing the need for RCTs on warfarin compared with no treatment in G4-G5D. Awaiting RCTs, it seems reasonable to treat selected patients on dialysis and NVAF with warfarin.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- direct oral anticoagulants
- end stage renal disease
- chronic kidney disease
- left atrial
- catheter ablation
- left atrial appendage
- venous thromboembolism
- heart failure
- newly diagnosed
- percutaneous coronary intervention
- ejection fraction
- peritoneal dialysis
- machine learning
- prognostic factors
- coronary artery disease
- acute coronary syndrome
- patient reported
- smoking cessation
- aortic valve
- patient reported outcomes